Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Jianjun Alan Xiao
Observed names:
J Xiao,
Jian-Jun Xiao,
Jian-jun Xiao,
Jianjun Xiao,
Xiao, Jianjun
Institution:
Zhongshan People's Hospital
Observed institutions:
Sun Yat-sen University,
CHI Health Creighton University Medical Center - Bergan Mercy,
Zhongshan People's Hospital,
Shaoxing Second Hospital,
First Affiliated Hospital of Nanchang University
ORCID:
0000-0002-8469-6134
Observed ORCID:
0000-0002-8469-6134
OpenAlex ID:
A5101777210
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms
2021
·
David P. Steensma
, Martin Wermke
, et al.
·
Leukemia
·
214
PDF
Shear stress activates ATOH8 via autocrine VEGF promoting glycolysis dependent-survival of colorectal cancer cells in the circulation
2020
·
Qiong Huang
, Shaowei Li
, et al.
·
Journal of Experimental & Clinical Cancer Research
·
71
PDF
Programmed Cell Death-1 Polymorphisms Decrease the Cancer Risk: A Meta-Analysis Involving Twelve Case-Control Studies
2016
·
Wenjing Dong
, Mancheng Gong
, et al.
·
PLoS ONE
·
65
PDF
miR-5195-3p Inhibits Proliferation and Invasion of Human Bladder Cancer Cells by Directly Targeting Oncogene KLF5
2017
·
Zhangjie Jiang
, Yida Zhang
, et al.
·
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics
·
47
Phase I/II study of H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer.
2021
·
Erika P. Hamilton
, Judy S. Wang
, et al.
·
Journal of Clinical Oncology
·
42
Hepatitis B Virus Infection Is Associated with Poor Prognosis in Patients with Advanced Non Small Cell Lung Cancer
2015
·
Jie-Wen Peng
, Dong-Ying Liu
, et al.
·
Asian Pacific Journal of Cancer Prevention
·
19
PDF
A phase IV study to evaluate the safety of fruquintinib in Chinese patients in real-world clinical practice
2024
·
Jin Li
, Zhiqiang Wang
, et al.
·
The Oncologist
·
15
PDF
Phase I study of H3B-6527 in hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC).
2021
·
Teresa Macarulla
, Victor Moreno
, et al.
·
Journal of Clinical Oncology
·
14
Phase 1b study of H3B-6545 in combination with palbociclib in women with metastatic estrogen receptor–positive (ER+), human epidermal growth factor receptor 2 (HER2)-negative breast cancer.
2021
·
Stephen R. D. Johnston
, Timothy J. Pluard
, et al.
·
Journal of Clinical Oncology
·
13
Efficacy and safety of HLX10, a novel anti-PD-1 antibody, in patients with previously treated unresectable or metastatic microsatellite instability-high or mismatch repair-deficient solid tumors: A single-arm, multicenter, phase 2 study.
2021
·
Shukui Qin
, Jin Li
, et al.
·
Journal of Clinical Oncology
·
13
Clinical Features and Prognostic Impact of Coexpression Modules Constructed by WGCNA for Diffuse Large B‐Cell Lymphoma
2020
·
Jianjun Xiao
, Xuemei Wang
, et al.
·
BioMed Research International
·
12
PDF
Prognostic Significance of the Peripheral Blood Absolute Monocyte Count in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma Receiving Systemic Chemotherapy
2014
·
Gui-Nan Lin
, Xiao-Mei Jiang
, et al.
·
Asian Pacific Journal of Cancer Prevention
·
9
PDF
Disproportionality analysis of drug-induced erectile dysfunction using FAERS database
2025
·
Xiaona Tian
, Dongqiang Luo
, et al.
·
Scientific Reports
·
6
PDF
Abstract P1-17-03: H3B-6545 in combination with palbociclib in women with metastatic estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 (HER2)-negative breast cancer, phase 1b study
2022
·
Stephen Johnston
, Timothy J Pluard
, et al.
·
Cancer Research
·
4
Safety of fruquintinib in Chinese patients with colorectal cancer: an age subgroup analysis from a phase IV real-world clinical practice study
2025
·
Yi Wang
, Yifu He
, et al.
·
Therapeutic Advances in Medical Oncology
·
2
Correction To: Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial
2022
·
Shukui Qin
, Jin Li
, et al.
·
British Journal of Cancer
·
2
PDF
Updated efficacy and safety results from the phase 2 study of serplulimab, a novel anti-PD-1 antibody, in patients with previously treated unresectable or metastatic microsatellite instability-high or mismatch repair-deficient solid tumors.
2022
·
Jin Li
, Shukui Qin
, et al.
·
Journal of Clinical Oncology
·
2
Abstract PS12-15: Pharmacokinetics of H3B-6545 in patients with locally advanced or metastatic estrogen receptor-positive HER2 negative breast cancer (ER+ and HER2- BC)
2021
·
Oneeb Majid
, Jianjun Alan Xiao
, et al.
·
Cancer Research
·
2
Management of Tumour Lysis Syndrome in Non-Hodgkin Lymphoma
2009
·
Frankie Wai Tsoi Cheng
, Jianjun Xiao
·
2
A phase IV study to evaluate the safety of fruquintinib in Chinese real-world clinical practice.
2023
·
Jin Li
, Zhi-Qiang Wang
, et al.
·
Journal of Clinical Oncology
Relative bioavailability of H3B-6545 tablets versus capsules and drug-drug interaction between H3B-6545 and pantoprazole.
2021
·
Jianjun Alan Xiao
, Hugh A Coleman
, et al.
·
Journal of Clinical Oncology
The protective mechanisms of Lycium Barbarum polysaccharides in non-alcoholic fatty liver disease
2011
·
Jianjun Xiao
, Ching C. Lau
, et al.
·
The HKU Scholars Hub (University of Hong Kong)
Abstract P3-09-05: Let-7 microRNAs Regulate a Novel Variant of Estrogen Receptor Alpha, ER-≥36, Nongenomic Estrogen Signal Pathway, and Tamoxifen Resistance in Breast Cancer
2010
·
Y Zhao
, C Deng
, et al.
·
Cancer Research
Show more works
View as search
Works count:
26
Citation count:
554
H-index:
11
I10-index:
11
Year
Topic
Type